<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113096</url>
  </required_header>
  <id_info>
    <org_study_id>ECP 250 - 15/16</org_study_id>
    <nct_id>NCT04113096</nct_id>
  </id_info>
  <brief_title>Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer</brief_title>
  <official_title>Use of Dibenzyl Trisulphide as a Chemotherapeutic Agent in Stage Four Cancer of the Breast, Prostate, Cervix and Colon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of The West Indies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of The West Indies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in
      Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate,
      cervix and colon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There have been many claims of the value of Guinea Hen weed in the treatment of different
      cancers. The preparation is readily available and used locally. The team proposes to validate
      the studies done on cancer cell lines by conducting a clinical trial to determine the
      clinical benefit in advanced and metastatic cancers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>For each condition there will be two arms of treatment. One arm will receive the investigational product and standard of care the other arm will receive placebo and standard of care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Cancer</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>50% change in the Prostate Specific Antigen Response (PSA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breast Cancer</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Changes in size of the metastatic legions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colon Cancer</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>50% change in the Carcinoembryonic Antigen (CEA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cervical Cancer</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>50% change in renal function (Renal output)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin Red Cell Test</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Blood - haemoglobin red cell count grams/decilitre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Platelets Tests</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Blood; platelet count per microlitre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea Tests</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Blood Urea Nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Creatinine</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Amount of creatinine in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Electrolytes</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Amount of electrolytes in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Calcium</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Amount of calcium in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Phosphorus</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Amount of phosphorus in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Test</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Blood prothrombin time (PT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Prothrombin Test</measure>
    <time_frame>Every 8 weeks upto 52 weeks</time_frame>
    <description>Partial thromboplastin time( PTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cell Test</measure>
    <time_frame>every 8 weeks up to 52 weeks</time_frame>
    <description>white cell count per microlitre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computed Tomography (CT) Scan</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>A pelvis baseline scan and level of metastases quantified by a single radiologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nuclear bone scintigraphy</measure>
    <time_frame>every 8 weeks up to 52 weeks</time_frame>
    <description>A bone scintigraphy or X-ray to show number and site of metastases noted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin Direct test</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Bilirubin direct, mmol per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin Indirect test</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Bilirubin indirect mmol per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphate level test (ALP)</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Amount of Alkaline Phosphate enzyme in blood units per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase test</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Level of the aspartate aminotransferase enzymes in the blood units per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl transferase test</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Level of the Gamma-glutamyl transferase units per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase test</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Level of Lactate dehydrogenase units per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiration</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Number of breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature measurement</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Temperature; degrees centigrade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Pulse-beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Survival Curves</measure>
    <time_frame>Every 8 weeks up to 52 weeks</time_frame>
    <description>Proportion of patients alive after administration of intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage IV Cancer of the Cervix</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Stage IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colon Cancer Stage IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervical Cancer Stage IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer of the Prostate Stage IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dibenzyl trisulphide capsules</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Breast Cancer Stage IV</arm_group_label>
    <other_name>Guineahen Weed capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dibenzyl trisulphide capsules</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Colon Cancer Stage IV</arm_group_label>
    <other_name>Guineahen Weed capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dibenzyl trisulphide capsules</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Cervical Cancer Stage IV</arm_group_label>
    <other_name>Guineahen Weed capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dibenzyl trisulphide capsules</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Cancer of the Prostate Stage IV</arm_group_label>
    <other_name>Guineahen Weed capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage IV Breast Cancer Placebo</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Breast Cancer Stage IV</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage IV: Colon Cancer Placebo</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Colon Cancer Stage IV</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cervical Cancer Stage IV Placebo</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Cervical Cancer Stage IV</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cancer of the Prostate Placebo</intervention_name>
    <description>20 mg once daily for 6 months</description>
    <arm_group_label>Cancer of the Prostate Stage IV</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: Greater than 12 years.

          -  Documented histologic evidence of cancer

          -  Staged as stage IV

          -  World Health Organization (WHO) Performance Status of between 0 and 2

          -  Radiological confirmation of metastases with bone scan or X ray, CT and/or MRI scan
             Exclusion Criteria

               -  Cancer stages less than stage 4

               -  Pregnant women

               -  Children 0 - 12 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAD Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the West Indies, Mona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Horace Fletcher, MBBS/DM</last_name>
    <phone>876 927 1145</phone>
    <email>horace.fletcher@uwimona.edu.jm</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilian Wharfe, MBBS/DM</last_name>
    <phone>876.927.1410</phone>
    <email>gilian.wharfe@uwimona.edu.jm</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medial Sciences</name>
      <address>
        <city>Kingston</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horace Fletcher, MBBS/DM</last_name>
      <phone>876.927.1145</phone>
      <email>horace.fletcher@uwimona.edu.jm</email>
    </contact>
    <contact_backup>
      <last_name>Gilian Wharfe, MBBS/DM</last_name>
      <phone>876.977.3942</phone>
      <email>gilian.wharfe@uwimona.edu.jm</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Jamaica</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

